Memorial Sloan Kettering Cancer Center

Jonathan Rosenberg discusses BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in advanced urothelial cancer, showing a 40% response rate in previously treated patients, and NKT2152, a HIF2a inhibitor for renal cell carcinoma, with a 26% response rate but potential hypoxia risks due to its long half-life.

86% (12/14) of evaluable patients with low-grade UTUC achieved complete response (CR) after Induction Treatment Phase with Padeliporfin VTP, which continues to show safety and efficacy. The Phase 3 ENLIGHTED study aims to enroll up to 100 patients globally, with enrollment expected to complete by early 2025.

PMV Pharmaceuticals' Q3 2024 Form 10-Q reports $21.9M in operating expenses, $19.2M net loss, and $0.37 net loss per share. The company is advancing PC14586 through clinical trials, received FDA Fast Track Designation, and restructured with a 30% workforce reduction. PMV expects to fund operations through 2026 with $197.9M in cash and equivalents.

86% of evaluable patients with low-grade UTUC achieved complete response after Padeliporfin VTP treatment in Phase 3 ENLIGHTED study, with safety and efficacy profiles consistent with prior results. The study aims to enroll up to 100 patients globally, with enrollment expected to complete by early 2025.

BostonGene presents six AI-driven studies at SITC 2024, advancing tumor microenvironment profiling, genomic analysis, biomarker identification, immune-related adverse event prediction, and novel drug targets for precision oncology.

Four NCI-designated cancer centers form Cancer AI Alliance (CAIA) with $40M+ funding from AWS, Deloitte, Microsoft, NVIDIA. CAIA aims to apply responsible AI to cancer data, ensuring security while transforming research and care. Fred Hutch Cancer Center leads, with CAIA expected to operate by end of 2024 and produce insights by 2025.

Aumolertinib improved progression-free survival in unresectable stage III NSCLC, with increased AEs in the experimental arm. New endocrine therapies and BCL-2 inhibitors are advancing treatment options, while ivonescimab showed efficacy over pembrolizumab in advanced NSCLC.

Drug repurposing offers faster, affordable solutions for rare diseases, leveraging existing data and streamlined regulatory pathways. Advances in technology, like AI and big data, accelerate the process. Challenges include navigating regulatory frameworks and high costs, but collaboration and public-private partnerships can overcome these obstacles, making drug repurposing crucial for improving access to effective treatments.

Inavolisib plus fulvestrant and palbociclib significantly improved progression-free survival (PFS) in HR+, HER2-, PIK3CA-mutated breast cancer patients, reducing progression risk by 57% compared to palbociclib alone (PFS 15.0 vs 7.3 months, HR 0.43). FDA approved inavolisib regimen in October 2024, supported by INAVO120 data.